Minister announces domestic packaging of 3 million imported CanSino jabs

ISLAMABAD: The government will import CanSino vaccine jabs in bulk to package 3 million doses locally, announced Minister for Planning and Development Asad Umar on Tuesday.

“We will be getting the bulk vaccine by mid-April from Cansino, from which 3 million doses can be made,” Asad, who is the minister in charge of pandemic operations, said in a tweet.

The first batch of 60,000 doses of the Chinese vaccine is arriving today [Tuesday], he said in a separate tweet. “This is the vaccine in which Pakistan participated in phase 3 trials, which was the first time ever that Pakistan had done so for any vaccine.”

The government is also expecting to receive one million doses of the Sinopharm vaccine early next month.

CanSino is one of the four vaccines approved by the Drug Regulatory Authority of Pakistan (DRAP), the other three being China’s Sinopharm, Russia’s Sputnik-V, and the Oxford University-AstraZeneca vaccine.

The company had last month released the interim efficacy results of a multi-country trial, which included Pakistan, showing 65.7 per cent efficacy in preventing symptomatic coronavirus cases and a 90.98 per cent success rate in stopping severe infections.

Pakistan is experiencing a third, deadlier wave with a sharp rise in new Covid-19 infections and deaths. It recorded 100 deaths in the last 24 hours, and 4,084 new infections, with a transmission rate of 8.8 per cent — meaning for every 100 individuals tested, 8.8 per cent tested positive for coronavirus.

The country has recorded 14,356 deaths and 663,200 infections since the pandemic began. Around two-thirds of ventilators and 80 per cent of oxygenated beds are occupied in hospitals in major cities, according to official data.

Last week, the government announced to have bought more than 1 million doses of Sinopharm and CanSino vaccines, the country’s first purchase from any manufacturer having previously relied on donations.

“We have purchased 1 million and 60,000 doses of Sinopharm and CanSino vaccines,” Asad said at the time. “We will be receiving the consignment before the end of March.”

“We want them to deliver that 7 million by the end of April, but they have not confirmed this yet. They might have some supply issues,” he added.

Authorities have so far relied on donations and on allocations from the World Health Organisation (WHO)-backed COVAX/GAVI initiative for developing nations.

The first COVAX/GAVI batch of up to 4 million doses of the Oxford-AstraZeneca vaccine had been due to be delivered in March but was delayed due to the issues the vaccine was facing worldwide, Umar said.

The government launched a vaccination campaign for the general public on March 10, starting with older people. The drive had begun with a focus on the oldest people in the community, generally over the age of 80, Minister of State for National Health Services Dr Faisal Sultan said.

The government is aiming to vaccinate around 70 million people out of the 220 million population to reach sufficient community immunity. 100 million people under 18 years of age not yet required to be vaccinated, it says.

Meanwhile, one of the first countries in the world to allow private imports of Covid-19 vaccines for sale on the open market, Pakistan has already received a batch of the Sputnik-V vaccine.

Authorities expect richer people will buy their own vaccination shots through this route, but the commercial administration of vaccines is yet to begin as the government settles pricing issues.

However, in a letter to Prime Minister Imran Khan, Transparency International has raised concerns about the private sale of vaccines, saying it will cause inequality and open the door to corruption.

Authorities have proposed a price of 8,449 rupees ($54.30) per pack of two injections of Sputnik V and 4,225 ($27.15) per injection for Convidecia, which will be CanSino’s trade name.

According to a mechanism approved by the government, the trade price for an imported vaccine will add a 40 per cent mark up to the landed cost, with another 15 per cent for retailers or hospitals.

Must Read

The AI Paradox

The use of Artificial Intelligence is revolutionary, defining new pathways in various aspects of the modern era including education. AI provides opportunities like efficient...

Defending the dollar

Epaper_24-12-23 LHR

Epaper_24-12-23 KHI